English

KERYX BIOPHARMACEUTICALS INC

EDGAR

KERX Quarterly report amendment (10-Q/A) · filed 2018-11-13

129 filing records in this dataset, filed from 2000-09-11 to 2018-11-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

28 million USD

2018 Q3 · USD

Exact inputs and evidence

Revenue: 28036000 USD Source

Operating margin

-52.38%

2018 Q3 · %

Exact inputs and evidence

Operating Income: -14686000 USD Source
Revenue: 28036000 USD Source

Operating cash flow

-23.4 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -78178000 USD Source
Operating Cash Flow: -54793000 USD Source

Free cash flow

-23.4 million USD

2018 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -78178000 USD Source
Operating Cash Flow: -54793000 USD Source
Capital Expenditure: 52000 USD Source
Capital Expenditure: 52000 USD Source

Cash and cash equivalents: 41.1 million USD 2018-09-30 Source
Exact value

41146000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 120 million shares 2018-09-30 Source
Exact value

120384764 shares

Reported share-count change

1.04% · 1.24 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

119144790 shares · 2017-09-30· Source
120384764 shares · 2018-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

94.2 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Revenue: 18682000 USD · 2017-10-01 – 2017-12-31 Source
Revenue: 21751000 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 25749000 USD · 2018-04-01 – 2018-06-30 Source
Revenue: 28036000 USD · 2018-07-01 – 2018-09-30 Source

Net income

-90.8 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Net income: -30429000 USD · 2017-10-01 – 2017-12-31 Source
Net income: -21896000 USD · 2018-01-01 – 2018-03-31 Source
Net income: -21518000 USD · 2018-04-01 – 2018-06-30 Source
Net income: -16995000 USD · 2018-07-01 – 2018-09-30 Source

Operating cash flow

-98.4 million USD

2017-10-01 – 2018-09-30

Exact inputs and evidence

Operating cash flow: -93489000 USD · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -73313000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -33430000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -54793000 USD · 2018-01-01 – 2018-06-30 Source
Operating cash flow: -33430000 USD · 2018-01-01 – 2018-03-31 Source
Operating cash flow: -78178000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -54793000 USD · 2018-01-01 – 2018-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2018-11-13.

Financial data available through: 2017-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2017-12-31
Operating income: 9 of 11 periods available· newest 2017-12-31
Net income: 9 of 11 periods available· newest 2017-12-31
Operating cash flow: 9 of 11 periods available· newest 2017-12-31
Capital expenditure: 9 of 11 periods available· newest 2017-12-31
Total assets: 9 of 11 periods available· newest 2017-12-31
Total liabilities: 9 of 11 periods available· newest 2017-12-31
Current assets: 9 of 11 periods available· newest 2017-12-31
Current liabilities: 9 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2017-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+89.6%

Prior period

USD 31.98 million

2016-01-01 – 2016-12-31
Current period

USD 60.64 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

60641000 − 31983000 = 28658000 USD

31983000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
60641000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Year-over-year change in Revenue: 28658000 USD Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 60641000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#227501 Filing: 000111422018000029 Input fundies:Revenue: 31983000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#226786 Filing: 000111422018000029
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.35 million

Prior period

−USD 161.1 million

2016-01-01 – 2016-12-31
Current period

−USD 163.44 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-163440000 − -161095000 = -2345000 USD

-161095000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-163440000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Year-over-year change in Net income: -2345000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -163440000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#199795 Filing: 000111422018000029 Input fundies:NetIncome: -161095000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#198800 Filing: 000111422018000029
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 6.89 million

Prior period

−USD 86.6 million

2016-01-01 – 2016-12-31
Current period

−USD 93.49 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-93489000 − -86604000 = -6885000 USD

-86604000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-93489000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Year-over-year change in Operating cash flow: -6885000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -93489000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197553 Filing: 000111422018000029 Input fundies:OperatingCashFlow: -86604000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197301 Filing: 000111422018000029
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-39.4%

Prior period

USD 2.07 million

2016-01-01 – 2016-12-31
Current period

USD 1.26 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

1257000 − 2074000 = -817000 USD

2074000 USD · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
1257000 USD · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Year-over-year change in Capital expenditure: -817000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1257000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214599 Filing: 000111422018000029 Input fundies:CapitalExpenditure: 2074000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214389 Filing: 000111422018000029
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 60.64 million 100% of revenue
Operating costs Derived USD 162.33 million 268% of revenue
Operating income −USD 101.69 million −168% of revenue
Tax, interest and other Derived USD 61.75 million 102% of revenue
Net income −USD 163.44 million −270% of revenue

Cash

Operating cash flow −USD 93.49 million −154% of revenue
Capital expenditure USD 1.26 million 2.1% of revenue
Free cash flow Derived −USD 94.75 million −156% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2009 Net income was higher than operating income, so the split is not drawn.
2010 Not shown: operating income or net income is not reported.
2011 Operating loss: operating costs were 675% of revenue.
2012 Not shown: operating income or net income is not reported.
2013 Operating loss: operating costs were 773% of revenue.
2014 Operating loss: operating costs were 1,128% of revenue.
2015 Operating loss: operating costs were 912% of revenue.
2016 Operating loss: operating costs were 484% of revenue.
2017 Operating loss: operating costs were 268% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2009 2009-01-01 – 2009-12-31	25191000	15376000 Derived	9815000	-670000 Derived	10485000	-5520000 Derived	Source 2009-01-01 – 2009-12-31: 25191000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: 9815000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: 10485000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -5516000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 4000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	0	21215000 Derived	-21215000	-884000 Derived	-20331000	-16231000 Derived	Source 2010-01-01 – 2010-12-31: 0 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -21215000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -20331000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -16208000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 23000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	5000000	33749000 Derived	-28749000	-626000 Derived	-28123000	-22879000 Derived	Source 2011-01-01 – 2011-12-31: 5000000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -28749000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -28123000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -22822000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 57000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	0	27079000 Derived	-27079000	-4358000 Derived	-22721000	-24787000 Derived	Source 2012-01-01 – 2012-12-31: 0 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -27079000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -22721000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -24763000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 24000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	7000000	54083000 Derived	-47083000	-351000 Derived	-46732000	-34665000 Derived	Source 2013-01-01 – 2013-12-31: 7000000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -47083000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -46732000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -34319000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 346000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	10825000	122054000 Derived	-111229000	289000 Derived	-111518000	-82490000 Derived	Source 2014-01-01 – 2014-12-31: 10825000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -111229000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -111518000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -81001000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 1489000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	13680000	124748000 Derived	-111068000	12077000 Derived	-123145000	-130234000 Derived	Source 2015-01-01 – 2015-12-31: 13680000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -111068000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -123145000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -127457000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 2777000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	31983000	154746000 Derived	-122763000	38332000 Derived	-161095000	-88678000 Derived	Source 2016-01-01 – 2016-12-31: 31983000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -122763000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -161095000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -86604000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2074000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	60641000	162332000 Derived	-101691000	61749000 Derived	-163440000	-94746000 Derived	Source 2017-01-01 – 2017-12-31: 60641000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -101691000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -163440000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -93489000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1257000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 60.6M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Revenue	25191000	Revenue: 25191000 Open source
20102010-12-31	Revenue	0	Revenue: 0 Open source
20112011-12-31	Revenue	5000000	Revenue: 5000000 Open source
20122012-12-31	Revenue	0	Revenue: 0 Open source
20132013-12-31	Revenue	7000000	Revenue: 7000000 Open source
20142014-12-31	Revenue	10825000	Revenue: 10825000 Open source
20152015-12-31	Revenue	13680000	Revenue: 13680000 Open source
20162016-12-31	Revenue	31983000	Revenue: 31983000 Open source
20172017-12-31	Revenue	60641000	Revenue: 60641000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

89.6% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Year over year	No prior comparable period	Revenue: 25191000 Open source
20102010-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 25191000 Open source
20112011-12-31	Year over year	No prior comparable period	Revenue: 5000000 Open source Revenue: 0 Open source
20122012-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 5000000 Open source
20132013-12-31	Year over year	No prior comparable period	Revenue: 7000000 Open source Revenue: 0 Open source
20142014-12-31	Year over year	54.6%	Revenue: 10825000 Open source Revenue: 7000000 Open source
20152015-12-31	Year over year	26.4%	Revenue: 13680000 Open source Revenue: 10825000 Open source
20162016-12-31	Year over year	133.8%	Revenue: 31983000 Open source Revenue: 13680000 Open source
20172017-12-31	Year over year	89.6%	Revenue: 60641000 Open source Revenue: 31983000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -167.7% 2017

Net margin -269.5% 2017

Free cash flow margin -156.2% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Operating margin	39%	Operating Income: 9815000 Open source Revenue: 25191000 Open source
20102010-12-31	Operating margin	Not reported	Operating Income: -21215000 Open source Revenue: 0 Open source
20112011-12-31	Operating margin	-575%	Operating Income: -28749000 Open source Revenue: 5000000 Open source
20122012-12-31	Operating margin	Not reported	Operating Income: -27079000 Open source Revenue: 0 Open source
20132013-12-31	Operating margin	-672.6%	Operating Income: -47083000 Open source Revenue: 7000000 Open source
20142014-12-31	Operating margin	-1,027.5%	Operating Income: -111229000 Open source Revenue: 10825000 Open source
20152015-12-31	Operating margin	-811.9%	Operating Income: -111068000 Open source Revenue: 13680000 Open source
20162016-12-31	Operating margin	-383.8%	Operating Income: -122763000 Open source Revenue: 31983000 Open source
20172017-12-31	Operating margin	-167.7%	Operating Income: -101691000 Open source Revenue: 60641000 Open source
20092009-12-31	Net margin	41.6%	Net Income: 10485000 Open source Revenue: 25191000 Open source
20102010-12-31	Net margin	Not reported	Net Income: -20331000 Open source Revenue: 0 Open source
20112011-12-31	Net margin	-562.5%	Net Income: -28123000 Open source Revenue: 5000000 Open source
20122012-12-31	Net margin	Not reported	Net Income: -22721000 Open source Revenue: 0 Open source
20132013-12-31	Net margin	-667.6%	Net Income: -46732000 Open source Revenue: 7000000 Open source
20142014-12-31	Net margin	-1,030.2%	Net Income: -111518000 Open source Revenue: 10825000 Open source
20152015-12-31	Net margin	-900.2%	Net Income: -123145000 Open source Revenue: 13680000 Open source
20162016-12-31	Net margin	-503.7%	Net Income: -161095000 Open source Revenue: 31983000 Open source
20172017-12-31	Net margin	-269.5%	Net Income: -163440000 Open source Revenue: 60641000 Open source
20092009-12-31	Free cash flow margin	-21.9%	Revenue: 25191000 Open source Operating Cash Flow: -5516000 Open source Capital Expenditure: 4000 Open source
20102010-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -16208000 Open source Capital Expenditure: 23000 Open source
20112011-12-31	Free cash flow margin	-457.6%	Revenue: 5000000 Open source Operating Cash Flow: -22822000 Open source Capital Expenditure: 57000 Open source
20122012-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -24763000 Open source Capital Expenditure: 24000 Open source
20132013-12-31	Free cash flow margin	-495.2%	Revenue: 7000000 Open source Operating Cash Flow: -34319000 Open source Capital Expenditure: 346000 Open source
20142014-12-31	Free cash flow margin	-762%	Revenue: 10825000 Open source Operating Cash Flow: -81001000 Open source Capital Expenditure: 1489000 Open source
20152015-12-31	Free cash flow margin	-952%	Revenue: 13680000 Open source Operating Cash Flow: -127457000 Open source Capital Expenditure: 2777000 Open source
20162016-12-31	Free cash flow margin	-277.3%	Revenue: 31983000 Open source Operating Cash Flow: -86604000 Open source Capital Expenditure: 2074000 Open source
20172017-12-31	Free cash flow margin	-156.2%	Revenue: 60641000 Open source Operating Cash Flow: -93489000 Open source Capital Expenditure: 1257000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -93.5M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Operating cash flow	-5516000	Operating Cash Flow: -5516000 Open source
20102010-12-31	Operating cash flow	-16208000	Operating Cash Flow: -16208000 Open source
20112011-12-31	Operating cash flow	-22822000	Operating Cash Flow: -22822000 Open source
20122012-12-31	Operating cash flow	-24763000	Operating Cash Flow: -24763000 Open source
20132013-12-31	Operating cash flow	-34319000	Operating Cash Flow: -34319000 Open source
20142014-12-31	Operating cash flow	-81001000	Operating Cash Flow: -81001000 Open source
20152015-12-31	Operating cash flow	-127457000	Operating Cash Flow: -127457000 Open source
20162016-12-31	Operating cash flow	-86604000	Operating Cash Flow: -86604000 Open source
20172017-12-31	Operating cash flow	-93489000	Operating Cash Flow: -93489000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -94.7M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Free cash flow	-5520000	Operating Cash Flow: -5516000 Open source Capital Expenditure: 4000 Open source
20102010-12-31	Free cash flow	-16231000	Operating Cash Flow: -16208000 Open source Capital Expenditure: 23000 Open source
20112011-12-31	Free cash flow	-22879000	Operating Cash Flow: -22822000 Open source Capital Expenditure: 57000 Open source
20122012-12-31	Free cash flow	-24787000	Operating Cash Flow: -24763000 Open source Capital Expenditure: 24000 Open source
20132013-12-31	Free cash flow	-34665000	Operating Cash Flow: -34319000 Open source Capital Expenditure: 346000 Open source
20142014-12-31	Free cash flow	-82490000	Operating Cash Flow: -81001000 Open source Capital Expenditure: 1489000 Open source
20152015-12-31	Free cash flow	-130234000	Operating Cash Flow: -127457000 Open source Capital Expenditure: 2777000 Open source
20162016-12-31	Free cash flow	-88678000	Operating Cash Flow: -86604000 Open source Capital Expenditure: 2074000 Open source
20172017-12-31	Free cash flow	-94746000	Operating Cash Flow: -93489000 Open source Capital Expenditure: 1257000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

108.9% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Liabilities / assets	21.4%	Total Liabilities: 8721000 Open source Total Assets: 40818000 Open source
20102010-12-31	Liabilities / assets	27.6%	Total Liabilities: 8866000 Open source Total Assets: 32114000 Open source
20112011-12-31	Liabilities / assets	28.6%	Total Liabilities: 12441000 Open source Total Assets: 43488000 Open source
20122012-12-31	Liabilities / assets	43.5%	Total Liabilities: 8075000 Open source Total Assets: 18569000 Open source
20132013-12-31	Liabilities / assets	25.3%	Total Liabilities: 15366000 Open source Total Assets: 60766000 Open source
20142014-12-31	Liabilities / assets	29.1%	Total Liabilities: 30144000 Open source Total Assets: 103628000 Open source
20152015-12-31	Liabilities / assets	66.4%	Total Liabilities: 171751000 Open source Total Assets: 258685000 Open source
20162016-12-31	Liabilities / assets	105.9%	Total Liabilities: 149723000 Open source Total Assets: 141427000 Open source
20172017-12-31	Liabilities / assets	108.9%	Total Liabilities: 172967000 Open source Total Assets: 158872000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.12× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Current assets / current liabilities	5.89×	Current Assets: 35521000 Open source Current Liabilities: 6032000 Open source
20102010-12-31	Current assets / current liabilities	4.64×	Current Assets: 28712000 Open source Current Liabilities: 6192000 Open source
20112011-12-31	Current assets / current liabilities	4.1×	Current Assets: 40004000 Open source Current Liabilities: 9767000 Open source
20122012-12-31	Current assets / current liabilities	1.88×	Current Assets: 15107000 Open source Current Liabilities: 8039000 Open source
20132013-12-31	Current assets / current liabilities	3.71×	Current Assets: 56928000 Open source Current Liabilities: 15328000 Open source
20142014-12-31	Current assets / current liabilities	3.36×	Current Assets: 98596000 Open source Current Liabilities: 29311000 Open source
20152015-12-31	Current assets / current liabilities	3.21×	Current Assets: 249294000 Open source Current Liabilities: 77606000 Open source
20162016-12-31	Current assets / current liabilities	6.17×	Current Assets: 132897000 Open source Current Liabilities: 21551000 Open source
20172017-12-31	Current assets / current liabilities	3.12×	Current Assets: 141566000 Open source Current Liabilities: 45420000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2009 2009-01-01 – 2009-12-31	USD 10.49 million Exact value Exact value: 10485000 USD 2009-01-01 – 2009-12-31: 10485000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2009-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: 10485000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: 10485000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420412012714/kerx-20111231.xml#22695 Filing: 000114420412012714 The citation records this snapshot. The page link may show a newer release later.	−USD 5.52 million Exact value Exact value: -5516000 USD 2009-01-01 – 2009-12-31: -5516000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2009-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -5516000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5516000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420412012714/kerx-20111231.xml#19698 Filing: 000114420412012714 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2009-01-01 – 2009-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2009-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420412012714/kerx-20111231.xml#24613 Filing: 000114420412012714 The citation records this snapshot. The page link may show a newer release later.	−USD 5.52 million Calculation and evidence -5516000 − 4000 USD Exact free cash flow: -5520000 USD 2009-01-01 – 2009-12-31: -5516000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2009-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -5520000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5516000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420412012714/kerx-20111231.xml#19698 Filing: 000114420412012714 Input fundies:CapitalExpenditure: 4000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420412012714/kerx-20111231.xml#24613 Filing: 000114420412012714 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 20.33 million Exact value Exact value: -20331000 USD 2010-01-01 – 2010-12-31: -20331000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2010-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -20331000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20331000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420413014537/kerx-20121231.xml#109505 Filing: 000114420413014537 The citation records this snapshot. The page link may show a newer release later.	−USD 16.21 million Exact value Exact value: -16208000 USD 2010-01-01 – 2010-12-31: -16208000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2010-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -16208000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16208000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420413014537/kerx-20121231.xml#141614 Filing: 000114420413014537 The citation records this snapshot. The page link may show a newer release later.	USD 23,000 Exact value Exact value: 23000 USD 2010-01-01 – 2010-12-31: 23000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2010-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 23000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 23000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420413014537/kerx-20121231.xml#142154 Filing: 000114420413014537 The citation records this snapshot. The page link may show a newer release later.	−USD 16.23 million Calculation and evidence -16208000 − 23000 USD Exact free cash flow: -16231000 USD 2010-01-01 – 2010-12-31: -16208000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 23000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2010-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -16231000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16208000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420413014537/kerx-20121231.xml#141614 Filing: 000114420413014537 Input fundies:CapitalExpenditure: 23000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000114420413014537/kerx-20121231.xml#142154 Filing: 000114420413014537 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 28.12 million Exact value Exact value: -28123000 USD 2011-01-01 – 2011-12-31: -28123000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2011-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -28123000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28123000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312514097931/kerx-20131231.xml#88261 Filing: 000119312514097931 The citation records this snapshot. The page link may show a newer release later.	−USD 22.82 million Exact value Exact value: -22822000 USD 2011-01-01 – 2011-12-31: -22822000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2011-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -22822000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22822000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312514097931/kerx-20131231.xml#81100 Filing: 000119312514097931 The citation records this snapshot. The page link may show a newer release later.	USD 57,000 Exact value Exact value: 57000 USD 2011-01-01 – 2011-12-31: 57000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2011-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 57000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 57000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312514097931/kerx-20131231.xml#82697 Filing: 000119312514097931 The citation records this snapshot. The page link may show a newer release later.	−USD 22.88 million Calculation and evidence -22822000 − 57000 USD Exact free cash flow: -22879000 USD 2011-01-01 – 2011-12-31: -22822000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 57000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2011-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -22879000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22822000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312514097931/kerx-20131231.xml#81100 Filing: 000119312514097931 Input fundies:CapitalExpenditure: 57000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312514097931/kerx-20131231.xml#82697 Filing: 000119312514097931 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 22.72 million Exact value Exact value: -22721000 USD 2012-01-01 – 2012-12-31: -22721000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2012-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -22721000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22721000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312515069937/kerx-20141231.xml#865499 Filing: 000119312515069937 The citation records this snapshot. The page link may show a newer release later.	−USD 24.76 million Exact value Exact value: -24763000 USD 2012-01-01 – 2012-12-31: -24763000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2012-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -24763000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24763000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312515069937/kerx-20141231.xml#859711 Filing: 000119312515069937 The citation records this snapshot. The page link may show a newer release later.	USD 24,000 Exact value Exact value: 24000 USD 2012-01-01 – 2012-12-31: 24000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2012-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312515069937/kerx-20141231.xml#865235 Filing: 000119312515069937 The citation records this snapshot. The page link may show a newer release later.	−USD 24.79 million Calculation and evidence -24763000 − 24000 USD Exact free cash flow: -24787000 USD 2012-01-01 – 2012-12-31: -24763000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 24000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2012-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -24787000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24763000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312515069937/kerx-20141231.xml#859711 Filing: 000119312515069937 Input fundies:CapitalExpenditure: 24000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312515069937/kerx-20141231.xml#865235 Filing: 000119312515069937 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 46.73 million Exact value Exact value: -46732000 USD 2013-01-01 – 2013-12-31: -46732000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2013-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -46732000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46732000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312516481950/kerx-20151231.xml#88130 Filing: 000119312516481950 The citation records this snapshot. The page link may show a newer release later.	−USD 34.32 million Exact value Exact value: -34319000 USD 2013-01-01 – 2013-12-31: -34319000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2013-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -34319000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34319000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312516481950/kerx-20151231.xml#82109 Filing: 000119312516481950 The citation records this snapshot. The page link may show a newer release later.	USD 346,000 Exact value Exact value: 346000 USD 2013-01-01 – 2013-12-31: 346000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2013-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 346000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 346000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312516481950/kerx-20151231.xml#84353 Filing: 000119312516481950 The citation records this snapshot. The page link may show a newer release later.	−USD 34.67 million Calculation and evidence -34319000 − 346000 USD Exact free cash flow: -34665000 USD 2013-01-01 – 2013-12-31: -34319000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 346000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2013-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -34665000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34319000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312516481950/kerx-20151231.xml#82109 Filing: 000119312516481950 Input fundies:CapitalExpenditure: 346000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000119312516481950/kerx-20151231.xml#84353 Filing: 000119312516481950 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 111.52 million Exact value Exact value: -111518000 USD 2014-01-01 – 2014-12-31: -111518000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2014-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -111518000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -111518000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422017000006/kerx-20161231.xml#189561 Filing: 000111422017000006 The citation records this snapshot. The page link may show a newer release later.	−USD 81 million Exact value Exact value: -81001000 USD 2014-01-01 – 2014-12-31: -81001000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2014-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -81001000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81001000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422017000006/kerx-20161231.xml#188804 Filing: 000111422017000006 The citation records this snapshot. The page link may show a newer release later.	USD 1.49 million Exact value Exact value: 1489000 USD 2014-01-01 – 2014-12-31: 1489000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2014-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 1489000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1489000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422017000006/kerx-20161231.xml#203581 Filing: 000111422017000006 The citation records this snapshot. The page link may show a newer release later.	−USD 82.49 million Calculation and evidence -81001000 − 1489000 USD Exact free cash flow: -82490000 USD 2014-01-01 – 2014-12-31: -81001000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 1489000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2014-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -82490000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -81001000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422017000006/kerx-20161231.xml#188804 Filing: 000111422017000006 Input fundies:CapitalExpenditure: 1489000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422017000006/kerx-20161231.xml#203581 Filing: 000111422017000006 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 123.15 million Exact value Exact value: -123145000 USD 2015-01-01 – 2015-12-31: -123145000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2015-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -123145000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123145000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197805 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 127.46 million Exact value Exact value: -127457000 USD 2015-01-01 – 2015-12-31: -127457000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2015-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -127457000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -127457000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197048 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	USD 2.78 million Exact value Exact value: 2777000 USD 2015-01-01 – 2015-12-31: 2777000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2015-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 2777000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2777000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214179 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 130.23 million Calculation and evidence -127457000 − 2777000 USD Exact free cash flow: -130234000 USD 2015-01-01 – 2015-12-31: -127457000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 2777000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2015-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -130234000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -127457000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197048 Filing: 000111422018000029 Input fundies:CapitalExpenditure: 2777000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214179 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 161.1 million Exact value Exact value: -161095000 USD 2016-01-01 – 2016-12-31: -161095000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2016-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -161095000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -161095000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#198800 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 86.6 million Exact value Exact value: -86604000 USD 2016-01-01 – 2016-12-31: -86604000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2016-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -86604000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -86604000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197301 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	USD 2.07 million Exact value Exact value: 2074000 USD 2016-01-01 – 2016-12-31: 2074000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2016-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 2074000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2074000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214389 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 88.68 million Calculation and evidence -86604000 − 2074000 USD Exact free cash flow: -88678000 USD 2016-01-01 – 2016-12-31: -86604000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2074000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2016-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -88678000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -86604000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197301 Filing: 000111422018000029 Input fundies:CapitalExpenditure: 2074000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214389 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 163.44 million Exact value Exact value: -163440000 USD 2017-01-01 – 2017-12-31: -163440000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Net Income: -163440000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -163440000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#199795 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 93.49 million Exact value Exact value: -93489000 USD 2017-01-01 – 2017-12-31: -93489000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Operating Cash Flow: -93489000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93489000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197553 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	USD 1.26 million Exact value Exact value: 1257000 USD 2017-01-01 – 2017-12-31: 1257000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Capital Expenditure: 1257000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1257000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214599 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.	−USD 94.75 million Calculation and evidence -93489000 − 1257000 USD Exact free cash flow: -94746000 USD 2017-01-01 – 2017-12-31: -93489000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1257000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KERYX BIOPHARMACEUTICALS INC · 2017-12-31 KERYX BIOPHARMACEUTICALS INC (edgar:1114220) Free cash flow: -94746000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:42:51Z Snapshot: 9f33fafa92cbc60d66d2620c836ddf0d8caf1d7267b23ffbe1f66d9b46f7b7d6 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1114220?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93489000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#197553 Filing: 000111422018000029 Input fundies:CapitalExpenditure: 1257000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1114220/000111422018000029/kerx-20171231.xml#214599 Filing: 000111422018000029 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

129 filings · 2,121 latest values · 2,121 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001114220, 1114220, KERX, edgar:1114220

Also known as KERYX BIOPHAMAEUTICALS INC, KERYX BIOPHARMACEUTICALS INC

KERYX BIOPHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation